Skip to main content
. 2021 May 22;35(12):3551–3560. doi: 10.1038/s41375-021-01276-4

Table 1.

Patients characteristics at study entry (n = 551).

Prior RUX No RUX p = value
Number of patients n = 277 (50.3%) n = 274 (49.7%)
Median age (range) 58 (30–75) 58 (29–75) p = 0.4
Patients gender (n = 551)
  Male n = 175 (63%) n = 173 (63%) p = 0.9
  Female n = 102 (37%) n = 101 (37%)
DIPSS at transplant (n = 421, 76%)
  Low n = 2 (1%) n = 11 (6%) p < 0.01
  Intermediate-1 n = 48 (21%) n = 69 (35%)
  Intermediate-2 n = 125 (56%) n = 76 (39%)
  High risk n = 49 (22%) n = 41 (20%)
JAK (n = 354, 64%)
  Positive n = 154 (79%) n = 134 (86%) p = 0.05
  Negative n = 44 (21%) n = 22 (14%)
Donor (n = 551, 100%)
  MRD n = 66 (24%) n = 100 (36%) p = 0.003
  MUD n = 192 (69%) n = 150 (55%)
  MMUD/MMRD n = 19 (7%) n = 26 (9%)
CMV status (n = 533, 97%)
  +/+ n = 113 (41%) n = 108 (41%) p = 0.56
  +/− n = 46 (20%) n = 55 (21%)
  −/− n = 90 (33%) n = 75 (29%)
  −/+ n = 23 (9%) n = 23 (9%)
Disease (n = 551, 100%)
  Primary myelofibrosis n = 185 (67%) n = 199 (73%) p = 0.1
  Post-ET/-PV n = 92 (33%) n = 75 (27%)
Median follow-up (months) 44 (6–87) 49 (2–91) p < 0.01
Conditioning regimen (n = 548, 99%)
  RIC n = 187 (67%) n = 164 (60%) p = 0.08
  MAC n = 90 (33%) n = 107 (40%)
Spleen size at transplant (palpable in cm) (n = 305) 10 (1–30) 8 (1–30) p = 0.4
Constitutional symptoms at transplant (n = 297, 55%) n = 159 (68%) n = 138 (61%) p = 0.1
Donor source (n = 551, 100%)
  BM n = 21 (8%) n = 23 (7.6%) p = 0.9
  PB n = 255 (91.6%) n = 250 (91%)
  CB n = 1 (0.4%) n = 1 (0.4%)
Karnofsky at transplant (n = 537, 97%)
  ≤80 n = 113 (42%) n = 89 (33%) p = 0.03
  ≥90 n = 154 (58%) n = 181 (67%)
Interval from diagnosis to transplant (months) 68 (2–430) 32 (2–527) p < 0.01